No Data
No Data
We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals, Inc. (SNDX): This Small-Cap Healthcare Stock Is A Good Buy Right Now
Foundation Medicine Partners With Syndax to Develop a Companion Diagnostic in Hematology and Support Efforts to Pursue Regulatory Approval for an Assay Based on the FoundationOneHeme Platform
Syndax Pharmaceuticals' (NASDAQ:SNDX) Growing Losses Don't Faze Investors as the Stock Climbs 4.4% This Past Week
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $34
Citi analyst Yigal Nochomovitz maintains $Syndax Pharmaceuticals(SNDX.US)$ with a buy rating, and adjusts the target price from $30 to $34.According to TipRanks data, the analyst has a success rate